Super Bowl, Hims

Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Doctor weighs in on controversial weight loss drug commercial
The ad from the telehealth company Hims & Hers promoted the company’s compounded weight loss drugs. The ad portrayed the obesity epidemic as a rigged game because of the greedy health care system. Dr.
Hims & Hers Super Bowl Spot Draws Drug-Industry Backlash
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto against weight-loss treatments priced “for profits, not patients,” after critici
Hims & Hers Super Bowl Ad Controversy - Here's The Latest
Hims & Hers faced backlash over its Super Bowl ad touting its compound weight loss drug while slamming pharmaceutical giants for profiting from America's obesity crisis. The company attracted flak from US Senators,
Fierce Healthcare2h
Hims & Hers sees 650% spike in traffic following Super Bowl ad as clash over compounded GLP-1s heats up
Hims & Hers hit the bulls-eye with its Super Bowl ad—it sparked a lot of attention from consumers to check out its brand and ...
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
Hims & Hers: Firing On All Cylinders, But Expensive
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
ThePrint15m
BJP’s Vijender Gupta urges L-G to implement PM-ABHIM, HIMS in Delhi
BJP MLA Vijender Gupta on Thursday urged Lieutenant Governor VK Saxena to implement the PM-ABHIM and the HIMS schemes in Delhi to help revive the city’s struggling public healthcare system. In a ...
GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hims & Hers Health: Explosive Growth Potential Ahead
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
Hims & Hers Option Trade Offers $410 Return Or 17% Discount
The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...
San Francisco company airs controversial Super Bowl ad despite multiple objections
Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...